Skip to main content
. Author manuscript; available in PMC: 2022 Nov 7.
Published in final edited form as: Prostate. 2019 Aug 21;79(14):1692–1704. doi: 10.1002/pros.23894

FIGURE 4.

FIGURE 4

WNT10B expression in PCa cell lines and patient specimens. A, Relative WNT10B expression in PrEC, HuSLC, PC3, and PC3M cells normalized to Rpl13a. WNT10B expression was significantly increased in all PCa cell lines relative to disease-free PrEC. P < .005, N = 3. Bars represent the mean ± SEM. B, RNA-seq analysis of WNT10B expression in localized and metastatic human PCa specimens expressed as FPKM. WNT10B mRNA levels were significantly increased in metastatic PCa compared with localized PCa (*P < .05). Metastatic samples were divided into pretreatment and posttreatment with Enz/Abi or taxane and WNT10B expression declined posttreatment in both groups, although this did not reach statistical significance. *P < .05. Bars represent the mean ± SEM. Abi, abiraterone; Enz, enzalutamide; FPKM, fragments per kilobase of transcript per million; PCa, prostate cancer; PrEC, prostate epithelial cell